Navigation Links
Pharmos Restructures Operations in Israel
Date:10/30/2007

ISELIN, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today it is undertaking a second phase of restructuring as it continues to optimize the balance between cash resources and its most promising scientific research and development programs. This second phase involves a workforce reduction from 23 to 8 employees in its Israeli subsidiary, Pharmos Ltd. The Company does not expect a material charge against operations to result from this undertaking.

The Israeli subsidiary will continue efforts to expand and exploit the potential of the Company's CB2 receptor-selective library of compounds, including preclinical development of PRS-639,058 for neuropathic pain. It will also work to complete the Phase 2a clinical trial of Pharmos' proprietary NanoEmulsion (NE) topical cream drug delivery system formulated with the NSAID diclofenac for osteoarthritis pain. The Phase 2a NE/diclofenac study is currently underway at several Israeli hospitals, with data anticipated in mid-2008.

This restructuring phase also calls for the Company to assess other means of financing these programs, such as the possibility of finding new investors to finance Pharmos Ltd. as an independent entity. Dr. Haim Aviv, the founder of Pharmos, will lead these efforts on behalf of the Company's Board of Directors. Other than leading this effort, Dr. Aviv has no management role in Pharmos.

The restructuring will have no effect on the Company's late-stage clinical development program with dextofisopam, which is currently in Phase 2b testing in the U.S. as a treatment for irritable bowel syndrome (IBS). The double-blinded study, which commenced in June 2007, is designed to enroll approximately 480 patients with data expected in 2009. Dextofisopam completed a successful Phase 2a IBS study in which it demonstrated a statistically significant improvement over placebo on the primary endpoint of adequate overall relief (n=141, p=0.033), and was very well tolerated. IBS affects roughly 10%-15% of U.S. adults and with a void of safe and effective available therapies represents a large, underserved market. Dextofisopam's novel non-serotonergic brain-gut mechanism holds the potential for a unique and innovative IBS treatment approach.

About Pharmos Corporation

Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation and autoimmune disorders. The Company currently has two programs in clinical testing: the Phase 2b study of dextofisopam as a treatment for IBS and the Phase 2a study of NE/diclofenac as a treatment for osteoarthritis pain. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective agonists. PRS-639,058, the leading CB2- selective agonist, has demonstrated promising preclinical data in neuropathic pain. Various other CB2-selective compounds from Pharmos' pipeline are in preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.


'/>"/>
SOURCE Pharmos Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. MSI puts on hold plans for operations in Chennai
2. Memory deprivation after operations
3. UK Plastic surgeons cash in as cosmetic operations soar
4. Culling Operations in Jalgaon To End Monday
5. Jalgaon: Third Phase Of Culling Operations Begin
6. Relief Operations In Indonesia’s Quake-Hit Area
7. Vietnam Considering Legalizing Sex Change Operations
8. Cancellations of Operations touch 22,000
9. Smokers Warned to Give up else Face Denial of Operations
10. Chinas First Gay Health Clinic Commences Operations
11. Operations Put Off Due to Dearth of Clean Equipments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
Breaking Medicine Technology: